Endovascular Engineering today announced the closing of a $15 million Series A1 financing co-led by Santé Ventures and Cordis. The Menlo Park, California–based startup is also called E2. It’s focused on developing advanced mechanical thrombectomy technology. Get the full story on our sister site Medical Tubing + Extrusion.
Cordis
InnovHeart appoints former J&J executive as CEO
InnovHeart this week announced that it appointed medtech veteran David Wilson as CEO. Wilson has more than 30 years of experience in medical device industry. He previously served in numerous leadership roles at Johnson & Johnson, including worldwide president of Cordis. Wilson has also served at J&J as president of Mentor, VP of Ethicon R&D […]
Cordis names new CFO
Cordis today announced that it has appointed Christopher Scully as chief financial officer. Scully will lead the interventional cardiovascular technology company’s financial and IT functions to accelerate Cordis’s growth. Before joining the company, Scully was executive VP and CFO for PPD. He played a role in the company’s IPO and its eventual sale to Thermo […]
Cordis names new chief medical officer
Cardiovascular technology developer Cordis announced today that it appointed Dr. George Adams as its new chief medical officer. Miami Lakes, Florida-based Cordis said in a news release that the hiring of Adams furthers its mission to differentiate itself as a technological leader and value-based global medical device company. “We are delighted to have Dr. Adams […]
Cordis recalls some Smart Flex vascular stent systems
Cordis recently issued a warning letter regarding an issue with its Smart Flex vascular stent system. Santa Clara, California–based Cordis’s field safety correction action informs users that some of its Smart Flex vascular stents have the potential for distal tip dislodgment or separation due to inadequate adhesive application. Get the full story on our sister […]
Cardinal Health completes $1B sale of Cordis business
Cardinal Health (NYSE: CAH) announced today that it has completed the sale of its Cordis business to private equity firm Hellman & Friedman. The $1 billion sales price included includes H&F’s assumption of certain liabilities and Cardinal Health’s retention of some working capital accounts. “As we shared previously, this divestiture demonstrates our disciplined portfolio evaluation […]
FDA says Cordis carotid artery stent recall is serious
The FDA has classified Cordis‘ recall of its Precise Pro Rx carotid system as Class I, the most serious kind of recall. Cordis in February recalled certain lots of its Precise Pro RX carotid stent systems because of a risk of separation of the atraumatic distal tip of the sheathed delivery system in patients. The […]
Cardinal Health to sell Cordis for $1B
Cardinal Health (NYSE: CAH) announced today that it will sell its Cordis business to private equity outfit Hellman & Friedman (H&F) for $1 billion. News of the deal — expected to close in the second half of 2021 — comes nearly six years after Cardinal Health bought Cordis and its minimally-invasive cardiovascular technology from J&J […]
Cordis recalls some Precise Pro RX carotid stent systems
Cordis, a Cardinal Health (NYSE:CAH) subsidiary, is recalling and removing certain lots of its Precise Pro RX carotid stent systems. The Precise Pro RX carotid stent system, which is used in patients with stenotic lesions of the carotid arteries, has the potential for the distal tip to become separated from the wire lumen on certain lots […]
